Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.

Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popović Z, Huang P, Bawendi MG, Boucher Y, Jain RK.

Nat Commun. 2013;4:2516. doi: 10.1038/ncomms3516.

2.

Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.

Friedberg MK, Cho MY, Li J, Assad RS, Sun M, Rohailla S, Honjo O, Apitz C, Redington AN.

Am J Respir Cell Mol Biol. 2013 Dec;49(6):1019-28. doi: 10.1165/rcmb.2013-0149OC.

PMID:
23841477
3.

AT1 antagonist modulates activin-like kinase 5 and TGF-beta receptor II in the developing kidney.

Yim HE, Kim MK, Bae IS, Kim JH, Choi BM, Yoo KH, Hong YS, Lee JW.

Pediatr Nephrol. 2006 Oct;21(10):1377-88. Epub 2006 Aug 1.

PMID:
16897002
4.

Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.

Kim S, Toyokawa H, Yamao J, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Inoue K, Matsui Y, Kwon AH.

Pancreas. 2014 Aug;43(6):886-90. doi: 10.1097/MPA.0000000000000125.

PMID:
24717824
5.

Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro.

Zhao Y, Peng J, Zheng L, Yu W, Jin J.

Prostate. 2010 Jun 1;70(8):899-905. doi: 10.1002/pros.21124.

PMID:
20135646
6.

Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells.

Subramanian V, Golledge J, Heywood EB, Bruemmer D, Daugherty A.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):397-405. doi: 10.1161/ATVBAHA.111.239897. Epub 2011 Nov 17.

7.

Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.

Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X.

Cancer Lett. 2013 Jan 28;328(2):318-24. doi: 10.1016/j.canlet.2012.10.006. Epub 2012 Oct 22.

PMID:
23092556
8.

Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.

He X, Gao X, Peng L, Wang S, Zhu Y, Ma H, Lin J, Duan DD.

Circ Res. 2011 Jan 21;108(2):164-75. doi: 10.1161/CIRCRESAHA.110.234369. Epub 2010 Dec 2.

9.

Effect of adrenotensin on cell proliferation is mediated by angiotensin II in cultured rat mesangial cells.

Xue H, Yuan P, Zhou L, Yao T, Huang Y, Lu LM.

Acta Pharmacol Sin. 2009 Aug;30(8):1132-7. doi: 10.1038/aps.2009.103. Epub 2009 Jul 13.

10.

The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.

Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T, Ohta T.

Cancer Lett. 2014 Dec 1;355(1):46-53. doi: 10.1016/j.canlet.2014.09.019. Epub 2014 Sep 16.

11.

Interstitial fluid flow and cyclic strain differentially regulate cardiac fibroblast activation via AT1R and TGF-β1.

Galie PA, Russell MW, Westfall MV, Stegemann JP.

Exp Cell Res. 2012 Jan 1;318(1):75-84. doi: 10.1016/j.yexcr.2011.10.008. Epub 2011 Oct 14.

12.

Crosstalk between the angiotensin and endothelin-system in the cerebrovasculature.

Konczalla J, Wanderer S, Mrosek J, Schuss P, Platz J, Güresir E, Seifert V, Vatter H.

Curr Neurovasc Res. 2013 Nov;10(4):335-45.

PMID:
23988026
13.

Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.

Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2008 Jan;12(1):57-66. Epub 2007 Nov 17.

PMID:
18026817
14.

H(2)S inhibits hyperglycemia-induced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation.

Xue H, Yuan P, Ni J, Li C, Shao D, Liu J, Shen Y, Wang Z, Zhou L, Zhang W, Huang Y, Yu C, Wang R, Lu L.

PLoS One. 2013 Sep 13;8(9):e74366. doi: 10.1371/journal.pone.0074366. eCollection 2013.

15.

Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts.

Gu J, Liu X, Wang QX, Tan HW, Guo M, Jiang WF, Zhou L.

Exp Cell Res. 2012 Oct 1;318(16):2105-15. doi: 10.1016/j.yexcr.2012.06.015. Epub 2012 Jun 27.

PMID:
22749815
16.

Fibronectin synthesis by high glucose level mediated proliferation of mouse embryonic stem cells: Involvement of ANG II and TGF-beta1.

Kim YH, Ryu JM, Lee YJ, Han HJ.

J Cell Physiol. 2010 May;223(2):397-407. doi: 10.1002/jcp.22048.

PMID:
20112290
17.

Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.

Ji Z, Huang C, Liang C, Chen B, Chen S, Sun W.

Cell Mol Immunol. 2005 Apr;2(2):150-4.

18.

Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy.

Manucha W, Carrizo L, Ruete C, Molina H, Vallés P.

Cell Mol Biol (Noisy-le-grand). 2005 Nov 8;51(6):547-55.

PMID:
16309579
19.

Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.

Therrien F, Lemieux P, Bélanger S, Agharazii M, Lebel M, Larivière R.

Eur J Pharmacol. 2009 Apr 1;607(1-3):126-34.

PMID:
19326569
20.

Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.

Kim HJ, Ryu JH, Han SW, Park IK, Paik SS, Park MH, Paik DJ, Chung HS, Kim SW, Lee JU.

Nephron Physiol. 2004;97(4):p58-65.

PMID:
15331931
Items per page

Supplemental Content

Write to the Help Desk